141 related articles for article (PubMed ID: 11454947)
1. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
Chapel S; Veng-Pedersen P; Hohl RJ; Schmidt RL; McGuire EM; Widness JA
J Pharmacol Exp Ther; 2001 Aug; 298(2):820-4. PubMed ID: 11454947
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
Biopharm Drug Dispos; 2004 May; 25(4):149-56. PubMed ID: 15108217
[TBL] [Abstract][Full Text] [Related]
3. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
Widness JA; Veng-Pedersen P; Schmidt RL; Lowe LS; Kisthard JA; Peters C
J Pharmacol Exp Ther; 1996 Dec; 279(3):1205-10. PubMed ID: 8968342
[TBL] [Abstract][Full Text] [Related]
4. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.
Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
J Pharmacol Exp Ther; 2003 Aug; 306(2):532-7. PubMed ID: 12750427
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow failure following severe injury in humans.
Livingston DH; Anjaria D; Wu J; Hauser CJ; Chang V; Deitch EA; Rameshwar P
Ann Surg; 2003 Nov; 238(5):748-53. PubMed ID: 14578739
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
Kinoshita H; Ohishi N; Kato M; Tokura S; Okazaki A
Arzneimittelforschung; 1992 Feb; 42(2):174-8. PubMed ID: 1610430
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
Yoon WH; Park SJ; Kim IC; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow connexin-43 expression is critical for hematopoietic regeneration after chemotherapy.
Presley CA; Lee AW; Kastl B; Igbinosa I; Yamada Y; Fishman GI; Gutstein DE; Cancelas JA
Cell Commun Adhes; 2005; 12(5-6):307-17. PubMed ID: 16531325
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
El-Komy MH; Widness JA; Veng-Pedersen P
Drug Metab Dispos; 2011 Apr; 39(4):603-9. PubMed ID: 21209249
[TBL] [Abstract][Full Text] [Related]
11. A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow.
Quinn J; Fisher PW; Capocasale RJ; Achuthanandam R; Kam M; Bugelski PJ; Hrebien L
Cytometry A; 2007 Aug; 71(8):612-24. PubMed ID: 17542025
[TBL] [Abstract][Full Text] [Related]
12. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
Kato M; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):520-7. PubMed ID: 9353365
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of in vivo murine erythropoietic response to sodium orthovanadate.
Aguirre MV; Juaristi JA; Alvarez MA; Brandan NC
Chem Biol Interact; 2005 Sep; 156(1):55-68. PubMed ID: 16137666
[TBL] [Abstract][Full Text] [Related]
14. Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.
Djazayeri K; Szilvássy Z; Peitl B; Németh J; Nagy L; Kiss A; Szabó B; Benko I
Eur J Pharmacol; 2005 Oct; 522(1-3):122-9. PubMed ID: 16213483
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors.
Martínez AM; Sastre A; Muñoz A; Badell I; Maldonado MS; Cubells J
Bone Marrow Transplant; 1998 Jul; 22(2):137-8. PubMed ID: 9707020
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns.
Melo AM; Costa MT; Porta V; Vaz FA
J Matern Fetal Neonatal Med; 2005 Jan; 17(1):55-8. PubMed ID: 15804788
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of erythropoietin in genetically anemic mice.
Kato M; Miura K; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
Drug Metab Dispos; 1998 Feb; 26(2):126-31. PubMed ID: 9456298
[TBL] [Abstract][Full Text] [Related]
18. Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
Widness JA; Schmidt RL; Hohl RJ; Goldman FD; Al-Huniti NH; Freise KJ; Veng-Pedersen P
Clin Pharmacol Ther; 2007 Jun; 81(6):873-9. PubMed ID: 17429351
[TBL] [Abstract][Full Text] [Related]
19. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
Woo S; Jusko WJ
Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats.
Kinoshita H; Ohishi N; Kato M; Tokura S; Okazaki A
Arzneimittelforschung; 1991 Sep; 41(9):1004-7. PubMed ID: 1796912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
